 For purposes of this study we have chosen bevacizumab Avastin, which will: a attain complete blockage vs. Macugen of intravitreal VEGF-A, and; b which is limited in its ability to penetrate tissues because it is a full antibody vs. Lucentis, an antibody fragment specifically designed for better tissue penetration, and is more likely to restore VEGF homeostasis within the developing retina. 